Material and Methods
Study Population
We included all cases of COVID-MDR (n=12) treated in the intensive care
units of two European tertiary care hospitals between March
15th and May 1st 2020 (University
Hospital Zurich, and Henri Mondor Hospital, Créteil). Non
COVID-19-related DRESS- (n=5; median REGISCAR score 5) and MDR-cases
(n=7) with similar affected body surface areas as the COVID MDR patients
(50-80%), treated in the University Hospital Zurich, were used as
control groups (Table 1). Diagnoses were based on clinical assessment,
identification of a culprit drug, laboratory values and skin
histopathology. At the time of diagnosis/biopsy, patients had not
received any treatment for their respective DDH. Clinical data were
collected and presented for all patients, blood and skin samples for
further analyses were only collected in the patient cohort from Zurich.
The study was conducted according to the ethical guidelines at the
respective institutions and the Helsinki Declaration (EK2020-01029).